 |
| |
| Sep-28-16 | Reiterated |
RBC Capital Mkts |
Outperform |
$83 → $108 |
|
| Sep-20-16 | Reiterated |
Needham |
Buy |
$47 → $81 |
|
| Sep-19-16 | Upgrade |
RBC Capital Mkts |
Sector Perform → Outperform |
$5 → $83 |
|
| Sep-19-16 | Upgrade |
Jefferies |
Underperform → Hold |
|
|
| Sep-19-16 | Reiterated |
Robert W. Baird |
Outperform |
$23 → $102 |
|
| Jul-22-16 | Reiterated |
Needham |
Buy |
$20 → $26 |
|
| Jun-09-16 | Upgrade |
Piper Jaffray |
Underweight → Neutral |
|
|
| Jun-07-16 | Upgrade |
Wedbush |
Neutral → Outperform |
$36 |
|
| Jun-01-16 | Reiterated |
Wedbush |
Outperform |
$14 → $23 |
|
| May-03-16 | Downgrade |
Leerink Partners |
Mkt Perform → Underperform |
|
|
| Apr-29-16 | Downgrade |
Jefferies |
Hold → Underperform |
|
|
| Apr-26-16 | Reiterated |
RBC Capital Mkts |
Sector Perform |
$7.50 → $5 |
|
| Apr-26-16 | Reiterated |
Needham |
Buy |
$53 → $20 |
|
| Apr-26-16 | Downgrade |
Sun Trust Rbsn Humphrey |
Neutral → Reduce |
|
|
| Apr-26-16 | Downgrade |
Piper Jaffray |
Neutral → Underweight |
|
|
| Apr-22-16 | Reiterated |
RBC Capital Mkts |
Sector Perform |
$14 → $7.50 |
|
| Mar-23-16 | Downgrade |
JMP Securities |
Mkt Perform → Mkt Underperform |
|
|
| Mar-01-16 | Reiterated |
Needham |
Buy |
$55 → $53 |
|
| Jan-19-16 | Downgrade |
RBC Capital Mkts |
Outperform → Sector Perform |
$62 → $15 |
|
| Jan-15-16 | Downgrade |
Piper Jaffray |
Overweight → Neutral |
|
|
|
|
| Sep-29-16 12:40PM | Catabasis Skyrockets on Sarepta Partnership |
| 11:34AM | Sarepta announces Duchenne research partnership with Cambridge's Catabasis at bizjournals.com |
| 10:41AM | One Biotech Crashes, the Other Skyrockets -- Here's Why at Motley Fool |
| 08:00AM | Catabasis Pharmaceuticals and Sarepta Therapeutics Announce a Joint Research Collaboration in Duchenne Muscular Dystrophy Business Wire |
| Sep-28-16 06:00PM | Sarepta Therapeutics Announces First Patient Dosed in Phase III Clinical Trial of SRP-4045 and SRP-4053 for the Treatment of Duchenne Muscular Dystrophy Amenable to Exon 45 or 53 Skipping Business Wire +5.31% |
| 04:21PM | Sarepta's Costly Muscular Dystrophy Drug Flirts With Big Pharma M&A |
| 03:14PM | Heres Why These Five Stocks Are Trading Higher Today at Insider Monkey |
| 12:21PM | Better Buy: BioMarin Pharmaceuticals Inc. vs. Sarepta Therapeutics Inc at Motley Fool |
| 11:15AM | Selling Into Strength Can Be a Great Strategic Move |
| 10:26AM | RBC Capital Markets more than doubles Sarepta price target, citing 'potential for real upside' at MarketWatch |
| 10:17AM | Sarepta Therapeutics (SRPT) Stock Climbs, Analysts Bullish on Exondys |
| 10:04AM | Sarepta: 'Yes, We're Aware Our Price Target is $50 Higher Than the Current Price' at Barrons.com |
| 08:03AM | 3 Stocks to Avoid in Healthcare at Motley Fool |
| Sep-27-16 02:47PM | Sareptas Manufacturing Challenge (SRPT) at Investopedia |
| Sep-26-16 12:43PM | BioMarin Takes Aim at Rival Sarepta (BMRN, SRPT) at Investopedia |
| 09:56AM | Why Wells Fargo, Sarepta, Delphi, UPS, and More Are Making Headlines at Insider Monkey |
| Sep-25-16 10:00AM | For Traders, Planning Is More Important Than the Plan |
| Sep-24-16 01:24PM | 2 Stocks I'd Never Buy, and 1 I'll Consider at Motley Fool |
| 07:27AM | The Woman Behind Sarepta Therapeutics' Success at Motley Fool |
| 01:00AM | [$$] Sarepta Still Has Upside at Barrons.com |
| Sep-23-16 06:50PM | Sarpeta Approval Challenged by FDA (SRPT) at Investopedia -5.15% |
| 05:45PM | Sarpeta Raises Offering After FDA Approval (SRPT) at Investopedia |
| 05:29PM | SAREPTA THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial St |
| Sep-22-16 06:00PM | Sarepta Therapeutics Announces Pricing of $300 Million Public Offering of Common Stock Business Wire +8.45% |
| 03:22PM | 3 Reasons Sarepta Shares Rallied Following News Of $225 Million Offering |
| 01:36PM | Sarepta Announces Offering of Common Stock (SRPT) at Investopedia |
| 12:59PM | Top trades for the 2nd half: BABA, SRPT & more |
| 12:45PM | 5 Stocks With Amazon-Like Growth Potential at Motley Fool |
| 11:04AM | I Am One of the Underinvested Bulls Right Now |
| 10:24AM | FDA Commish Says Sarepta's DMD Study Should Be Retracted |
| 09:35AM | How Sarepta Is Cashing In on Its FDA Homerun at 24/7 Wall St. |
| 08:27AM | Rite Aid Corporation, WCI Communities & Other Stocks in Spotlight Following Earnings, M&A News and More at Insider Monkey |
| 07:39AM | [video]Stock Futures Rise as Wall Street Finds Relief in a Patient Fed |
| Sep-21-16 08:58PM | Sarepta Wins Favorable USPTO Decisions (SRPT) at Investopedia |
| 05:48PM | [$$] Sarepta to Sell Up to $225 Million of Stock at The Wall Street Journal |
| 04:32PM | 'Blockbuster Franchises' Spark M&A Fever For Sarepta, Ariad, Biotechs |
| 04:17PM | Sarepta (SRPT) Stock Slides in After-Hours Trading on Public Offering |
| 04:16PM | Sarepta sales slump after company announces $225 million stock offering at MarketWatch |
| 04:00PM | Sarepta Therapeutics Announces Proposed Public Offering of Common Stock Business Wire |
| 02:26PM | Sarepta's New Drug May Make It a Takeover (SRPT) at Investopedia |
| 01:34PM | Sarepta Therapeutics: BioMarin Still Wants a Piece of the Action at Barrons.com |
| 11:58AM | Sarepta to open Andover manufacturing site soon at bizjournals.com |
| 11:50AM | Patent Trial And Appeal Board Hands Sarepta Another Big Win |
| 08:39AM | Biotech Stock Roundup: Tobira Soars on Acquisition Deal, FDA Says Yes to Sarepta DMD Drug |
| 08:31AM | SAREPTA THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers |
| 08:23AM | At $300,000 a year, Sareptas new drug is considered a steal at MarketWatch |
| Sep-20-16 07:58PM | FDA Approval Leads 75% Rise in Sarepta (SRPT) at Investopedia +13.87% |
| 05:25PM | SAREPTA THERAPEUTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits |
| 05:15PM | Sarepta Therapeutics Announces Favorable USPTO Decisions in Exon 51 and Exon 53 Composition of Matter Patent Interference Cases against BioMarin Pharmaceutical Business Wire |
| 04:52PM | Biotechs Still Hot As Sarepta Drug Approval Provides A Shot In Arm |
| 04:38PM | Sarepta Muscular Dystrophy Drug Will Cost $300K; Acquisition Target? |
| 04:11PM | [$$] Sarepta jumps after drugs regulator boost at Financial Times |
| 04:07PM | Why PTC Therapeutics, Inc. Gave Back As Much As 10% on Tuesday at Motley Fool |
| 03:12PM | [$$] Sarepta Soars 100% in a Week Yet Remains a Buy at Barrons.com |
| 03:01PM | Forget Sarepta Therapeutics, Here Are 3 Other Biotech Stocks to Buy at Motley Fool |
| 02:17PM | Does Sarepta Therapeutics Inc.'s FDA Win Make Shares a Buy? at Motley Fool |
| 01:49PM | Biotechs Still Hot As Sarepta Drug Approval Provides A Shot In Arm |
| 01:49PM | Was Sarepta's Big Win a Big Mistake for the FDA? at Motley Fool |
| 12:22PM | Here's Why Sarepta Therapeutics, Inc's Stock is Jumping Again at Motley Fool |
| 11:46AM | Sarepta shares jump 13%, extending Monday's surge on drug approval at CNBC |
| 11:44AM | Sarepta Therapeutics Shares Buoyed by RBC Upgrade at TheStreet |
| 11:32AM | Why Sarepta Approval is Good News for BioMarin, Alexion at Barrons.com |
| 11:26AM | Sarepta Therapeutics (SRPT) Stock Surges, Cowen Upgrades on FDA Drug Approval |
| 11:24AM | FDA grants accelerated approval to Sareptas Duchenne drug at bizjournals.com |
| 10:25AM | Company News for September 20, 2016 |
| 10:13AM | Sarepta Stock Nearly Doubles on FDA Approval for DMD Drug |
| 09:51AM | Puma Biotechnology: Sarepta Isn't the Only Biotech Getting a Boost From the FDA at Barrons.com |
| 09:42AM | Stocks Open Higher; Housing Starts Miss Views |
| 09:17AM | Approving A Muscular Dystrophy Drug Ignites A Civil War At The FDA at Forbes |
| 08:53AM | Morning Movers: Sarepta Gains on Upgrade; Wells Fargo Rises at Barrons.com |
| 08:45AM | Top Analyst Upgrades and Downgrades: American Electric Power, Broadcom, Ford, GM, JD.com, Sarepta, Valeant Pharmaceuticals and More at 24/7 Wall St. |
| 08:19AM | Morning Movers: CHK, WFC, SRPT |
| 06:55AM | Biotech Stock Mailbag: Sarepta Therapeutics Approval Edition |
| 06:00AM | Jim Cramer's Top Takeaways: Anadarko Petroleum, Coach, Seres Therapeutics |
| 02:07AM | Sarepta Soars to 150% Q3 Gains, Wal-Mart Closes Jet Deal, SeaWorld Sinks & More at Insider Monkey |
| 12:18AM | [$$] FDA Approves Sareptas Muscular Dystrophy Drug at The Wall Street Journal |
| 12:18AM | [$$] The Boys Who Beat the FDA at The Wall Street Journal |
| 12:00AM | Fierce Debate at FDA on Whether Drug Decision Sets New Standard at Bloomberg |
| Sep-19-16 08:01PM | Why PTC Therapeutics Shares Skyrocketed 20.6% Today at Motley Fool +73.85% |
| 07:49PM | [$$] The Boys Who Beat the FDA at The Wall Street Journal |
| 07:08PM | Cramer Remix: Another speculative biotech with tremendous upside at CNBC |
| 07:00PM | Cramer Remix: Another speculative biotech with tremendous... |
| 06:56PM | How To Predict The Next Sarepta (FDA Approval Stock) And Win Big at Forbes |
| 05:59PM | Final Trade: GM, SRPT & more |
| 05:51PM | Sarepta's big FDA win |
| 05:46PM | Why Sarepta Pharmaceuticals, Tech Data, and Cliffs Natural Resources Jumped Today at Motley Fool |
| 05:30PM | Cause For Celebration In The Duchenne Muscular Dystrophy Community at Forbes |
| 05:29PM | Why Sarepta Therapeutics Soared 74% Today at Motley Fool |
| 05:15PM | [$$] FDA Approves Sarepta's Dystrophy Drug at The Wall Street Journal |
| 05:04PM | Sarepta shares leap 90% after FDA approves drug at CNBC |
| 04:34PM | Biotech stock explodes 73% after the FDA approves the first drug to treat a rare muscle disorder |
| 04:10PM | Sarepta Stock Soars On FDA OK For Muscular Dystrophy Drug |
| 04:09PM | Biotechnology ETFs Rally on Sarepta FDA Drug Approval |
| 04:05PM | [$$] Sarepta Still a Buy After Expedited FDA Approval at Barrons.com |
| 02:45PM | Sarepta's very good day |
| 02:27PM | Sarepta Analysts Turn Bullish After Duchenne Muscular Dystrophy Drug Eteplirsen Gets Approval |
| 01:52PM | Sarepta Therapeutics upgraded by RBC Capital Mkts |
| 01:44PM | SAREPTA THERAPEUTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits |
| 01:39PM | Sarepta Therapeutics Announces FDA Accelerated Approval of EXONDYS 51 (eteplirsen) injection, an Exon Skipping Therapy to Treat Duchenne Muscular Dystrophy (DMD) Patients Amenable to Skipping Exon 51 Business Wire |
| 01:32PM | Short Hills Capital CIO Weiss Discusses Sarepta Therapeutic (SRPT) Stock Surge Today |
|
|
|
|
| Sarepta Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery and development of RNA-based therapeutics for the treatment of rare, infectious, and other diseases. The company's lead product candidate is Eteplirsen, an antisense phosphorodiamidate morpholino oligomer therapeutic, which is in Phase III clinical development for the treatment of individuals with Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease caused by the absence of dystrophin. It is also developing exon-skipping drugs for the treatment of DMD; and therapeutic candidates for the treatment of infectious diseases, such as influenza, Marburg, and Ebola. The company has a strategic alliance with Charley's Fund, Inc. to support the development of product candidates using its proprietary exon-skipping technologies; and a license agreement with the University of Western Australia for the use of antisense sequences in the treatment of DMD. Sarepta Therapeutics, Inc. was founded in 1980 and is headquartered in Cambridge, Massachusetts. |
|
| Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
| Kaye Edward M. MD | President, CEO & CMO | Sep 22 | Option Exercise | 8.28 | 40,179 | 332,682 | 117,162 | Sep 26 04:23 PM | | Howton David T | SVP, General Counsel | Sep 22 | Option Exercise | 13.90 | 7,000 | 97,300 | 28,453 | Sep 26 04:19 PM | | Kaye Edward M. MD | President, CEO & CMO | Sep 22 | Sale | 60.00 | 40,179 | 2,410,740 | 76,983 | Sep 26 04:23 PM | | Howton David T | SVP, General Counsel | Sep 22 | Sale | 60.00 | 7,000 | 420,000 | 21,453 | Sep 26 04:19 PM | | Howton David T | SVP, General Counsel | Sep 19 | Option Exercise | 13.90 | 8,000 | 111,200 | 11,168 | Sep 21 09:28 PM | | Kaye Edward M. MD | President, CEO & CMO | Sep 19 | Option Exercise | 6.94 | 24,352 | 168,941 | 89,983 | Sep 21 09:29 PM | | Aphale Jayant | VP, Technical Operations | Sep 19 | Option Exercise | 4.62 | 35,000 | 161,700 | 36,490 | Sep 21 09:31 PM | | Aphale Jayant | VP, Technical Operations | Sep 19 | Sale | 50.00 | 35,000 | 1,750,000 | 11,490 | Sep 21 09:31 PM | | Kaye Edward M. MD | President, CEO & CMO | Sep 19 | Sale | 50.00 | 24,352 | 1,217,600 | 76,983 | Sep 21 09:29 PM | | Howton David T | SVP, General Counsel | Sep 19 | Sale | 50.00 | 9,304 | 465,200 | 3,168 | Sep 21 09:28 PM | | Kaye Edward M. MD | SVP Interim CEO & CMO | Sep 14 | Sale | 30.00 | 24,557 | 736,710 | 76,983 | Sep 16 04:04 PM | | BEHRENS M KATHLEEN | Director | Mar 16 | Buy | 14.54 | 10,000 | 145,433 | 21,855 | Mar 16 08:15 PM | | BEHRENS M KATHLEEN | Director | Mar 14 | Buy | 16.54 | 65,000 | 1,075,276 | 112,166 | Mar 16 08:15 PM | | Barry Richard | Director | Mar 14 | Buy | 15.66 | 75,000 | 1,174,185 | 3,241,014 | Mar 16 08:09 PM |
|
|
|
|
|
|
